JPWO2020246528A1 - - Google Patents

Info

Publication number
JPWO2020246528A1
JPWO2020246528A1 JP2021524890A JP2021524890A JPWO2020246528A1 JP WO2020246528 A1 JPWO2020246528 A1 JP WO2020246528A1 JP 2021524890 A JP2021524890 A JP 2021524890A JP 2021524890 A JP2021524890 A JP 2021524890A JP WO2020246528 A1 JPWO2020246528 A1 JP WO2020246528A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021524890A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020246528A1 publication Critical patent/JPWO2020246528A1/ja
Priority to JP2025010012A priority Critical patent/JP2025061775A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021524890A 2019-06-04 2020-06-04 Pending JPWO2020246528A1 (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025010012A JP2025061775A (ja) 2019-06-04 2025-01-23 痛風又は高尿酸血症の治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019104534 2019-06-04
PCT/JP2020/022039 WO2020246528A1 (ja) 2019-06-04 2020-06-04 痛風又は高尿酸血症の治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025010012A Division JP2025061775A (ja) 2019-06-04 2025-01-23 痛風又は高尿酸血症の治療薬

Publications (1)

Publication Number Publication Date
JPWO2020246528A1 true JPWO2020246528A1 (https=) 2020-12-10

Family

ID=73653292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524890A Pending JPWO2020246528A1 (https=) 2019-06-04 2020-06-04
JP2025010012A Pending JP2025061775A (ja) 2019-06-04 2025-01-23 痛風又は高尿酸血症の治療薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025010012A Pending JP2025061775A (ja) 2019-06-04 2025-01-23 痛風又は高尿酸血症の治療薬

Country Status (8)

Country Link
US (1) US20220323441A1 (https=)
EP (1) EP3981469B1 (https=)
JP (2) JPWO2020246528A1 (https=)
KR (1) KR20220016861A (https=)
CN (1) CN113924145A (https=)
AU (1) AU2020287549B2 (https=)
CA (1) CA3149714A1 (https=)
WO (1) WO2020246528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121648131A (zh) * 2020-12-08 2026-03-13 学校法人东日本学园 细胞内atp增强剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) * 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
JP2016520133A (ja) * 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2019107412A1 (ja) * 2017-11-28 2019-06-06 静岡県公立大学法人 固体分散体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019104534A (ja) 2017-12-13 2019-06-27 大日本印刷株式会社 ロール体梱包箱
JP2021127289A (ja) * 2018-04-27 2021-09-02 日本ケミファ株式会社 縮合ピリミジン誘導体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121153A1 (ja) * 2004-06-14 2005-12-22 Nippon Chemiphar Co., Ltd. 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤
JP2016520133A (ja) * 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2019107412A1 (ja) * 2017-11-28 2019-06-06 静岡県公立大学法人 固体分散体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
丹野 史枝: "固体分散体キャリヤとしての添加剤HPMCAS(ヒプロメロース酢酸エステルコハク酸エステル)の物性に関する考察", 薬剤学, vol. 73, no. 4, JPN6019003583, 2013, pages 214 - 222, ISSN: 0005601447 *
尾上誠良: "第3章 非晶質固体分散体", 難水溶性薬物の経口製剤化技術最前線(監修 川上亘作), JPN6020028038, 6 July 2016 (2016-07-06), pages 127 - 135, ISSN: 0005601446 *
柏原俊夫ほか: "第4章 経口投与製剤の設計と開発のストラテジー", 経口投与製剤の設計と評価(編集者 橋田充), JPN6020028036, 1995, pages 47 - 67, ISSN: 0005601445 *

Also Published As

Publication number Publication date
WO2020246528A1 (ja) 2020-12-10
AU2020287549B2 (en) 2026-01-29
CA3149714A1 (en) 2020-12-10
KR20220016861A (ko) 2022-02-10
AU2020287549A1 (en) 2022-01-27
JP2025061775A (ja) 2025-04-11
EP3981469A1 (en) 2022-04-13
EP3981469B1 (en) 2024-11-20
US20220323441A1 (en) 2022-10-13
EP3981469A4 (en) 2023-06-21
CN113924145A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021016821A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021016996A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021013944A2 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016142A2 (https=)
BR112019016138A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250123